Senesco Technologies, Inc. – "Reconsidering the Entire Cancer Treatment Approach"

Publishing & Media

Share Tweet

Senesco Technologies, Inc. – "Reconsidering the Entire Cancer Treatment Approach"

BRIDGEWATER, NJ / ACCESSWIRE / April 1, 2014 / Senesco Technologies, Inc. (OTCQB: SNTI) today published a new blog post on The Chairman's Blog, written by the Company's President and CEO, Dr. Leslie J. Browne. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his new blog, Dr. Browne reflects on a new way of approaching cancer treatment. Rather than thinking of it as a disease that needs to be attacked, he suggests that cancer be thought of as "a native part of the body that simply has too much enthusiasm, too much growth, and needs to be 'taught' when and how to stop." Read the full blog post from Dr. Leslie Browne on (

About Senesco Technologies

Senesco Technologies is a clinical-stage biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to eliminate cancer cells and protect healthy cells from premature death. The Company is currently in a Phase 1b/2a trial with a product candidate that is designed to treat B-cell cancers, which include multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's B-cell lymphomas. The technology was developed over the last 15 years through the discovery that the genetic pathway for cell growth control is common to both plants and humans. For more information, please visit or connect with us on Facebook, Twitter, LinkedIn and Google+.

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment.


SOURCE: Senesco Technologies and